Welcome! Defeating Merkel cell carcinoma begins here.

The critical first step is to find a Merkel cell carcinoma specialist.

It is critical that each case be reviewed by a multidisciplinary team, including surgical oncologists, radiation oncologists, medical oncologists, and dermatologists with significant experience in managing MCC, in order to develop a plan for the patient.

To find healthcare professionals experienced with Merkel cell carcinoma, start with our list of verified specialists.

Find a Specialist

Make sure your primary care team is knowledgeable and takes action.

Merkel cell carcinoma is rare, and it's common for many medical professionals to be unsure of where to start. When a diagnosis occurs, it is imperative that your medical team is knowledgeable and able to carry out an MCC specialist's plan.

Our clinical team recommends that all healthcare providers follow the NCCN guidelines for MCC to bring them up to speed on MCC and how to care for MCC patients.

Get the Guide

Consider joining a patient-based group

A diagnosis of Merkel cell carcinoma is a life-changing experience. Support from others—in the form of advice, recommendations for local healthcare providers, or sharing personal victories—can help ease the burden many MCC patients and their families feel.

We encourage you to make connections; it’s been proven to help.

Get Support

The latest advancements in treatment

Diagnostic Yield of Staging Brain MRI is Low in Merkel Cell Carcinoma: A Single-Institution Cohort Study

Merkel cell carcinoma, fortunately, rarely spreads to the brain, unlike several other types of cancer including melanoma. This study from Dr. David Miller’s team at Massachusetts General Hospital shows that unless there is some specific reason to suspect it (bad headaches, alteration in ability to...

Read More

Merkel cell carcinoma can be indolent: A case with 7 locoregional recurrences over 15 years highlights the importance of patient-tailored management

Patients who develop recurrences or metastases usually have poor prognoses and are often treated aggressively. We report a case of a man with an indolent, unusually long course of MCC over 15 years with 7 locoregional recurrences before developing distant metastases. Because he had 4 major comorbidi...

Read More

Intersection of Two Checkpoints: Could Inhibiting the DNA Damage Response Checkpoint Rescue Immune Checkpoint-Refractory Cancer?

There is an urgent need to find ways to help patients who do not have a persistent response to immune ‘checkpoint’ therapy for MCC. This review details surprising new findings from multiple labs that suggest such patients might benefit from blocking the ‘sensor’ a cancer cell uses to verify ...

Read More
View all the latest news and publications